Commissioning Policy: Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and vasculitis of the peripheral nervous system (adults)

Document first published:
Page updated:
Topic:
,
Publication type:

This policy document outlines the arrangements for funding of the Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and vasculitis of the peripheral nervous system (adults) treatment for the population in England.

Document

Commissioning Policy: Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and vasculitis of the peripheral nervous system (adults)

Commissioning Policy: Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and vasculitis of the peripheral nervous system (adults)

  • PDF
  • 65 KB
  • 14 pages